Osteoporosis is widely distributed condition characterized by bone weakness making it more fragile and easier to be fractured. Various elements enter in bone structure making it rigid to tolerate body weight and any accident. Many factors had a role in its progression, like age, gender, taking medications and genetic variations in enzymes responsible for vitamin D metabolism. The aim of our study is to evaluate role of polymorphism of metabolic enzyme CYP24A1 on responding to vitamin D in postmenopausal osteoporotic women. Method: 40 postmenopausal women were followed up for two months and took 50000IU/week of vitamin D during study period, and 30 postmenopausal women without osteoporosis as a control group. Blood sample were taken pre- and post-treatment to determine responder to vitamin D therapy. Results: regarding vitamin D level, there is a significant difference between responder and non-responder at pre-treatment level. GG genotype of rs2762934 was presented in higher percent in patients group (non-response one), and AA genotype of rs4809957 was the predominant one with a negative correlation to the responsiveness to vitamin D therapy. Conclusions: The homozygote wild GG genotype of rs2762934 predict vitamin D non-responsiveness in sample of osteoporotic postmenopausal women. The AA genotype of the same SNP substantially increases the responsiveness. While AA of rs4809957 associate with non-responsiveness. This study will implicate in correct choosing the desired dose of vitamin D for desired osteoporotic women to get better response and avoid any harmful effect of vitamin D overdose.
Key words: CYP24A1, Osteoporosis, single nucleotide polymorphism, post-menopausal, vitamin D
|
